Telix Pharmaceuticals is trading at A$15.64, down 4.05%, with no confirmed catalyst identified.
- No company announcement or reliable report directly explains the October 13, 2026 move; the latest listed ASX filings predate the session.
- The ITM acquisition was reported earlier, in September, and available coverage does not establish it as the cause of the decline.
- Broad U.S. indices were essentially flat, offering no clear same-direction market explanation.